Nastech Breaks Out New RNAi Technologies, Evades Questions About Possible Deal for Dicer-Substrates
October 12, 2006
Nastech Breaks Out New RNAi Technologies, Evades Questions About Possible Deal for Dicer-Substrates
At an analyst and institutional investor day, Nastech’s CSO outlined a modification technology the company has developed for siRNA stability and a delivery approach incorporating peptides and lipids. He also mentioned the company’s use of 27-mer siRNAs.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Regulus Selects HCV Drug Candidate, Will Develop without Partner GSK
May 16, 2013 / Gene Silencing News - Scripps, Novartis Team Uncovers New Details of Guide RNA, Argonaute2 Interaction
May 16, 2013 / Gene Silencing News - Gradalis Releases New Clinical Data on Cancer Vaccine
May 16, 2013 / Gene Silencing News - Former Traversa Exec Forms New Company to Develop Oligo-modification Tech
May 16, 2013 / Gene Silencing News - Tekmira on Track to Move Cancer Drug into Phase II, Name New Clinical Candidate in ‘13
May 16, 2013 / Gene Silencing News